Covid-19 roundup: Till­man Gern­gross inks deal to bring an­ti­body can­di­date to In­dia; At FDA's re­quest, mR­NA vac­cine mak­ers will ex­pand tri­als for chil­dren ages 5-11

A week af­ter it was re­port­ed that In­dia’s Covid-19 death toll could be in the mil­lions, an­ti­body leg­end Till­man Gern­gross has inked a deal to de­vel­op Ada­gio’s lead can­di­date for the treat­ment and pre­ven­tion of the virus in south­ern Asia.

Ada­gio is join­ing hands with Bio­con Bi­o­log­ics to man­u­fac­ture and com­mer­cial­ize a treat­ment based on ADG20 in In­dia and “se­lect emerg­ing mar­kets,” the com­pa­nies an­nounced on Mon­day. Un­der the agree­ment, Ada­gio will pro­vide Bio­con with ma­te­ri­als and know-how to make the ther­a­py, in­clud­ing da­ta from on­go­ing Phase II/III tri­als and (if all goes well) ac­cess to its po­ten­tial EUA pack­age.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER